Navigation Links
Targeted antibacterial agent rapidly created in response to serious food safety pathogen
Date:3/14/2012

South San Francisco, CA (March 14, 2012): A highly targeted bactericidal protein against the life-threatening foodborne E. coli O104 strain was rapidly created using AvidBiotics' antibacterial Purocin protein technology, making use of rapidly acquired, published, draft genomic sequence data as detailed in a new publication in PLoS ONE. The strategy described offers a rapid-response platform with the potential to create targeted agents for use against emerging bacterial pathogens within days-to-weeks of acquiring the pathogen's genome sequence.

"AvidBiotics has created a highly versatile technology platform for the generation of antibacterial proteins that specifically target and rapidly kill bacterial strains, offering important benefits in food security," said AvidBiotics' scientist, Dean Scholl, Ph.D., lead author on the new publication. "In collaboration with scientists from the U.S. Department of Agriculture, we've now shown that we can quickly generate such Purocin proteins against an emerging pathogen using only data acquired from its genome sequence, without necessarily having immediate access to the pathogen itself. This technology, in combination with the ever-increasing speed in which genome sequences can be generated and DNA synthesized, should provide a valuable tool for responding to newly emerging, re-emerging, and ever-changing bacterial threats." The E. coli O104 strain, which initially emerged in Germany in spring 2011, was ultimately responsible for close to 4,000 illnesses and 48 deaths.

The AvidBiotics authors and their collaborators at the U.S. Department of Agriculture, Western Regional Research Center, describe how, using published genomic data from the German E. coli outbreak strain, they identified an O-antigen-specific prophage tail spike protein encoded in the pathogen's genome. They synthesized the identified gene and fused it to the tail fiber gene of an R-type bacteriocin (a defense protein produced by certain bacteria against competing strains), and expressed the novel, engineered, antibacterial protein so that the tail fiber fusion was incorporated into an R-type bacteriocin structure. The resulting engineered protein demonstrated the ability to specifically bind and rapidly kill all tested E. coli strains that produce the O104 lipopolysaccharide antigen, including the German outbreak strain isolated from affected patients. None of many tested E. coli strains lacking the O104 antigen was sensitive to the O104-targeted protein, ensuring no unintended collateral damage.

About the AvidBiotics Antibacterial Protein Platform

AvidBiotics genetically engineers bactericidal proteins from R-type bacteriocins, proteins produced by some Pseudomonas aeruginosa strains for the purpose of killing competing bacteria. AvidBiotics' antibacterial proteins specifically kill bacteria by binding to the bacterial cell and punching a hole in the cell envelope, causing membrane depolarization and rapid cell death.

AvidBiotics has previously demonstrated that Purocin proteins can be engineered to recognize and kill in a highly targeted and specific manner a variety of bacteria, including E. coli, Salmonella, and Shigella, thus serving as a platform for the production of numerous highly specific antibacterial agents. AvidBiotics is collaborating with food safety and hygiene company, Ecolab, Inc. (NYSE: ECL), to develop antibacterial proteins for use against E. coli O157:H7 in processing meat and other foods.

In addition to E. coli, a cause of both serious diarrheal disease and recurrent urinary tract infections, AvidBiotics is also currently developing Avidocin proteins against Pseudomonas aeruginosa, a common cause of severe pneumonia and wound infections, Clostridium difficile, the most common cause of hospital-acquired infections, and Acinetobacter, a bacterium associated with serious, often broadly antibiotic-resistant infections in Intensive Care Units and with injuries incurred by U.S. military deployed in Iraq and Afghanistan.


'/>"/>

Contact: Joan Kureczka
Joan@kureczka-martin.com
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Related biology technology :

1. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
2. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
3. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
4. Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
5. Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer
6. Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
7. Epeius Biotechnologies REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
8. Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
9. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
10. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
11. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland ... from Platts Global Energy for their platform technology to produce a revolutionary ... 18th Platts Global Energy Awards, held in New York on Thursday, Dec. 8. ...
(Date:12/9/2016)... TORONTO , Dec. 9, 2016 /PRNewswire/ - Portage ... Securities Exchange: PBT.U), is pleased to announce that Biohaven ... New Haven, Connecticut (PRWEB) Dec ... "Company" or "Biohaven") announced today that the U.S. Food ... drug designation request covering its drug candidate BHV-0223, an ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , ... Inc. (ESI). Mr. Murray will bring valuable expertise ... experience in leading international business teams. As the National Division Leader, ... uphold Eurofins, status as the global leader in bio-analytical testing services. ... , , ...
Breaking Biology Technology:
(Date:12/2/2016)... 1, 2016 The report "Biometric ... Future Technology (Iris Recognition System), Vehicle Type (Passenger ... Forecast to 2021", published by MarketsandMarkets, the market ... 2016, and is projected to grow to USD ... 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):